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The clinical trials are serious endeavors in terms of cost
and the risks entailed in generating the best-practice
evidence. The science of clinical trials needs to be
considered in essence in order to design studies which
answer clinically meaningful questions. There are
serious hazards to the safety of the participants once
they sign the informed consent to undertake the
experiment. Generally the design of the trial is set before
actual recruitment of the patients. Any change in the
conduct of the trial is considered fraudulent behavior.
The conventional parallel arm trial has well defined
principles for design and analysis. Contrary to the
popular belief the analysis of the clinical trial is simple
contingent on the design of the trial. With correct design,
the analysis is simple and straight forward.1 However,
there is an increasing awareness that some of the
assumptions that were made before the start of the trial
turn out to be wrong. The adaptive design challenges
some of these assumptions and takes in to account the
information as it accrues. This piece discusses issues
related to the trial design.
It is surprising to note that the most important aspect of
clinical trials is left to element of chance alone.
Randomization ensures that elements, known or
otherwise, are distributed equally in two groups. It is
expected that the outcome in the two groups will be
attributed to the intervention rather than baseline
characteristics of the participants.1 The science of
sample size calculation is also based on certain
assumptions which need to be there in order to know the
working numbers.2 This is also far from being an exact
science contrary to the popular belief. However, without
the numbers, the actual logistics and other practical
planning will be impossible. Consider, for example, the
mortality or the effect size in the control group was
substantially higher (or lower) making the assumptions
related to the response rate in the intervention group
somewhat redundant. Alternatively, certain arms of the
trial like a dosing schedule might show a substantial
benefit over others.3 Research team is left with the
option of either to complete the trial and plan another
project keeping in view the findings or change the design
of the trial on some 'predefined criteria'? The latter is
the case with adaptive trial designs which has been
proposed by the Pharmaceutical Research and Manu-
facturers of American (PhRMA) in their introductory
white paper.4 The former option will delay introduction of
novel compound in to clinical care, if proven to have
value. The delay can be in terms of many years.
Generally speaking, it takes about 12 - 13 years for the
new compound to get the licensing approval.
Clinical trials are grouped in to various stages based on
the stage of the drug or vaccine development. Phase I
and II are considered to be early phase trial which focus
on the safety, tolerability and pharmacokinetics of the
drug during the development phase. Since the focus is
on the safety in the early phase trials, therefore, the
sample size is deliberately kept low, i.e. in the range of
50 - 80 healthy volunteers.5 The phase three trials
typically explore the therapeutic efficacy of the agent
against a placebo or gold standard treatment in those
affected with the disorder. The phase IV or post-
marketing surveillance collects the information after its
regulatory approval on long-terms side effects or other
adverse events.
It is important to recognize that sometime the distinction
between the phases is not clear cut. Phase I and II can
be merged to look at the tolerability and bioequivalence
and phase II and III are merged to test the efficacy in
those who are recognized to be high risk for the illness.
Adaptive trial design takes this in to account and could
have the potential to merge the early phase trials with
the therapeutic efficacy checked in the phase III trials.6
For example, a trial could start with various dosages of
the therapeutic agent A (for e.g. 5 mg, 10 mg and 15 mg)
and only the best dose (results) are carried forward to
the stage II of the trial, thereby  reducing the time
required to develop and license a potentially beneficial
medicinal product.6 There are various definitions of the
adaptive trial design but the key components which
make the trial adaptive is change in the conduct of the
trial based on unblinded results. The change can be
related to the sample size re-estimation, allocation ratio
(1:2 vs. 1:1) in favor of favorable dose/intervention or
dropping one arms of the trial altogether are based on
interim analysis. The criteria are pre-defined in terms of
changes to patients' accrual and the statistical power
required demonstrating the efficacy of the results.4 An
independent Data Safety and Monitoring Board (DSMB)
carries out the interim analysis and recommend the
changes in a manner which does not affect the blinding
of the participants and the investigators. Recently, it has
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been suggested that the sponsor (Pharmaceutical
Industry or University) should also be made part and
parcel of the DSMB since cost is also a matter of
discussion once the trial design is changed.7,8 Although
there are no set characteristics of the adaptive trials,
changes in the specific design features of the trials make
them adaptive. The general parallel arm trial can be
modified to fit the specific requirement in the cluster-
randomized, non-inferiority and factorial trial design.
The cluster randomized trial (CRT) is ideally suited to
deliver interventions targeted towards a groups rather
than individual. The intervention might be targeted at
group level and the outcome is measured at the patient
level.9 Generally, there is a close association between
various group members and independence cannot be
assumed, which has a bearing on the design.10
Geographical demarcation, villages and towns make
natural clusters for intervention. However, they might
differ in terms of important variables like socio-
economic status, housing, and other important baseline
covariates. In such cases, clusters are generally
stratified by variables associated with the outcome
measure. Randomization is planned at the level of each
stratum. In analyzing the CRT researcher has to take in
to account the design effect and the between-cluster
correlation. The design effect has to do with the
correlation between the individuals within the cluster
(intra-cluster correlation coefficient) and the number of
individuals within the clusters.11 The design effect is
considered to be the sampling variation of the
parameter, as estimated by the square root of the
standard error.12 Another important statistics, which
researcher has to consider, is the inter-cluster
correlation. The inter-cluster correlation ranges from -1
to +1, implying perfect correlation at +1 and otherwise
at -1. Stratification on variables which are correlated with
the outcome tends to increase the precision of the study.
Therefore, sample size needs to take stratification in to
account with randomization planned at the level of each
strata.12 Allocation without consideration of the baseline
risk factors tends to distribute these variables unequally
in the intervention groups, with subsequent loss of
power to detect the difference in these groups.
Stratification tends to increase the power to detect the
effect estimate in each stratum.13 Care has to be taken
that clusters are geographically far enough in order to
avoid the issue of contamination, i.e. participants talking
to each other and sharing the knowledge related to
intervention thereby unblinding the others.
The design to test the effectiveness of two active
interventions against a control  can also be done through
a factorial trial design. The intervention will be assessed
in the combination of 2 x 2 x 2 (8) groups with each unit
randomized at least 3 times in to various combinations
of treatment plans. The main disadvantage with the
factorial designs is lack of power to detected 'interaction'
among the combination of interventions.14 One of the
main reasons for conducting a factorial design is to test
multiple interventions in a single trial thereby saving the
resources with the assumption of lack of interaction
between their combinations. However, if such an
interaction occurs, the trial is underpowered to detect the
effect in the subgroups. The other disadvantage of the
factorial trial has to do with the practical management
and the compliance of the participants. As the number of
interventions increases the trial management becomes
more cumbersome.15 Patients also might not want to try
different combinations and grow vary of the participation.
The non-inferiority and equivalence trials look to test the
new intervention against a gold standard.16,17 If there is
an already established intervention which is efficacious
and well established that rationale for new drug
development is poor. However, if  the new intervention
has less side effects or better mode of delivery then non-
inferiority trial can look to demonstrate that the new
intervention is as good as the standard one or is no more
clinically inferior than standard one. The minimal clinical
detrimental effect is identified in advance and used to
estimate the sample size and power of the study. In
terms of statistics, lower tail or one sided confidence
interval is examined in order to see the effect estimate.
The measured intervention may  turn out to be non-
inferior or better than the standard intervention.
In conclusion, the clinical trial research has increased in
recent years with added complexities of the intervention
in itself. Specialized programmes and courses are being
developed to aid the researchers. It is time that
credentialing bodies like College of Physicians and
Surgeons Pakistan make concerted efforts along with
other stakeholders of clinical trials to develop the
research-capacity among physicians in Pakistan.19
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